Source comparison
MK-677 Studied Deep Sleep Optimization: Clinical Trial Comparison
Copinschi et al. (1997, JCEM) Healthy young men (n=8) 25mg nightly 7 days +50% Stage 4 duration +55% vs baseline No REM suppression; intact circadian rhythm Chapman et al. (1996, J Clin Endocrinol Metab) Elderly adults (n=32) 2 months +35% delta-wave amplitude
This comparison does not assign a generated winner or score.
- Copinschi et al. (1997, JCEM)
- Healthy young men (n=8)
- 25mg nightly
- 7 days
- +50% Stage 4 duration
- +55% vs baseline
- No REM suppression; intact circadian rhythm
- Chapman et al. (1996, J Clin Endocrinol Metab)
- Elderly adults (n=32)
- 2 months
- +35% delta-wave amplitude
- +72% vs baseline
- Reversed age-related slow-wave sleep decline
- Svensson et al. (1998, J Clin Endocrinol Metab)
- GH-deficient adults (n=24)
- 25mg daily
- 8 weeks
- +40% Stage 3–4 duration
- IGF-1 normalized to age-matched controls
- Improved sleep quality scores without sedation
- Murphy et al. (2006, Ann Neurol)
- Obese adults with OSA (n=14)
- No significant change
- +60% vs baseline
- Sleep apnea events unchanged; GH elevation intact
- The Murphy trial highlights a critical constraint: MK-677 studied deep sleep optimization doesn't overcome mechanical airway obstruction. Patients with moderate-to-severe obstructive sleep apnea showed GH and IGF-1 elevation but no reduction in apnea-hypopnea index (AHI). The slow-wave sleep extension was blunted compared to non-OSA populations, likely because airway collapse events fragment sleep regardless of hormonal signaling. For research protocols, screening out OSA is essential if sleep architecture is a primary endpoint.